

Please type a plus sign (+) inside this box

Approved for use through 4/30/2003. OMB 0651-0731
SUBSTITUTE for PTO/SB/04A (2-03). Information Disclosure Statement by Applicant
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO
INFORMATION DISCLOSURE

STATEMENT BY APPLICANT
JUL 14 2003 (use as many sheets as necessary)

1 of 3

COMPLETE IF KNOWN

Application Number: 09/831,182

Filing Date July 18, 2001

First Named Inventor Colloca, Stefano

Group Art Unit 1648

Examiner Name Winkler, U

Attorney Docket Number **ITR0056E**

RECEIVED
17.2.2003
160012901

RECEIVED
SEP 1 2 2002
ECHO CENTER 1600/2300

**Examiner
Signature**

Date Considered

9/27/04

**Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.*

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Customer requested form: "IDS Form" (IDS Bolder, March & Co., Inc., 06/27/2003)

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

JUL 14 2003

(use as many sheets as necessary)

TRADEMARK SHEET

2

of

3

COMPLETE IF KNOWN	
Application Number	09/831,182
Filing Date	July 18, 2001
First Named Inventor	Colloca, Stefano
Group Art Unit	1648
Examiner Name	Winkler, U.
Attorney Docket Number	ITR0056P

RECEIVED
TECH CENTER 1600/2900
SEP 1 3 2003

RECEIVED
TECH CENTER 1600/2900
JUL 1 1 2003

OTHER NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
W		Baron, U. et al. "Co-regulation of two gene activities by tetracycline via a bidirectional promoter", Nucleic Acids Research, 1995, Vol. 23, pp. 3605-3606
		Brough, D. et al. "A Gene Transfer Vector-Cell Line System for Complete Functional Complementation of Adenovirus Early Regions E1 and E4", Journal of Virology, 1996, Vol. 70, pp. 6497-6501
		Bett, A. et al. "An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3", Proc. Natl. Acad. Sci. USA, 1994, Vol. 91, pp. 8802-8806
		Calos, M. "The potential of extrachromosomal replicating vectors for gene therapy", TIG, 1996, Vol. 12, pp. 463-466
		Calos, M. "Stability without a centromere", Proc. Natl. Acad. Sci. USA, 1998, Vol. 95, pp. 4084-4085
		Deuschle, U. et al. "Tetracycline-Reversible Silencing of Eukaryotic Promoters", Molecular and Cellular Biology, 1995, Vol. 15, pp. 1907-1914
		Engelhardt, J. et al. "Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver", Proc. Natl. Acad. Sci. USA, 1994, Vol. 91, pp. 6196-6200
		Freundlieb, S. et al. "A Tetracycline Controlled Activation/Repression System with Increased Potential for Gene Transfer into Mammalian Cells", The Journal of Gene Medicine, 1999, Vol. 1, pp. 4-12
		Gossen, M. et al. "Transcriptional Activation by Tetracyclines in Mammalian Cells", Science, 1995, Vol. 268, pp. 1766-1769
		Hitt, M. et al. "Techniques for Human Adenovirus Vector Construction and Characterization", Methods in Molecular Genetics, 1995, Vol. 7, pp. 13-30
		Hitt, M. et al. "Human Adenovirus Vectors for Gene Transfer into Mammalian Cells", Advances in Pharmacology, 1997, Vol. 40, pp. 137-206
		Kozarsky, K. et al. "In Vivo Correction of Low Density Lipoprotein Receptor Deficiency in the Watanabe Heritable Hyperlipidemic Rabbit with Recombinant Adenoviruses", The Journal of Biological Chemistry, 1994, Vol. 269, pp. 13695-13702
		Krougliak, V. et al. "Development of Cell Lines Capable of Complementing E1, E4, and Protein IX Defective Adenovirus Type 5 Mutants", Human Gene Therapy, 1995, Vol. 6, pp. 1575-1586
		No, D. et al. "Ecdysone-inducible gene expression in mammalian cells and transgenic mice", Proc. Natl. Acad. Sci. USA, 1996, Vol. 93, pp. 3346-3351
P		Parks, R. et al. "A helper-dependent adenovirus vector system: Removal of helper virus by Cre-mediated excision of the viral packaging signal", Proc. Natl. Acad. Sci. USA, 1996, Vol. 93, pp. 13565-13570

Examiner Signature

Ute Winkler

Date Considered

4/27/04

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 06/27/2003

Substitute for form 1449A/PTO		COMPLETE IF KNOWN	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			
<i>(use as many sheets as necessary)</i>			
Sheet	3	of	3
		Attorney Docket Number	
		ITR0056P	

Examiner
Signature

Ken Weller

Date Considered

4/27/04

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

09/831182

JC08 Rec'd PCT/PTO 04 MAY 2001

EL652176619US

Form PTO-1449 (Modified)	ATTY DOCKET NO. B-4175PCT 618769-8	U.S. SERIAL NO. Not yet assigned
LIST OF PATENTS AND PUBLICATIONS STATEMENT	INTERNATIONAL APPLICATION NO. PCT/IT99/00356	INTERNATIONAL FILING DATE 8 November 1999
	APPLICANT(S) Stefano COLLOCA	
	FILING DATE Concurrently herewith	GROUP Not yet assigned

May 4, 2001

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	ISSUE DATE	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO
W		2 738 575	03/14/97	FR	—	—	NO
1		98/13510	04/02/98	WO			
		00/12740	03/09/00	WO			
4		98/13499	04/02/98	WO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

--	--	--

EXAMINER <i>Wu</i>	DATE CONSIDERED 2/9/03
-----------------------	---------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.